Table 1.
Basic characteristics of the included studies.
| No. | Study name | Drug name | Drug type | Treatment regimen | Number of evaluable patients | Peripheral neuropathy | Previous therapy | Phase | Randomized controlled trial (RCT) | Tumor type |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cohen et al. (14) | Pembrolizumab | PD-1 | Pembrolizumab vs. (Methotrexate, Docetaxel, or Cetuximab) | 480 | 7 | Platinum-based | III | RCT | Head-and-neck squamous cell carcinoma |
| 2 | Schmid et al. (15) | Atezolizumab | PD-L1 | Atezolizumab + Nab-paclitaxel vs. Placebo + Nab-paclitaxel | 890 | 195 | NO | III | RCT | Advanced Triple-Negative Breast Cancer (BC) |
| 3 | Horn et al. (16) | Atezolizumab | PD-L1 | Atezolizumab + Carboplatin + Etoposide vs. Placebo + Carboplatin + Etoposide | 394 | 6 | NO | III | RCT | SCLC |
| 4 | Socinski et al. (17) | Atezolizumab | PD-L1 | Atezolizumab + BCP vs. BCP | 787 | 274 | NO | III | RCT | Metastatic non squamous NSCLC |
| 5 | Paz-Ares et al. (18) | Pembrolizumab | PD-1 | Pembrolizumab + Carboplatin + Paclitaxel vs. Placebo + Carboplatin + Paclitaxel | 558 | 102 | NO | III | RCT | Metastatic squamous NSCLC |
| 6 | Shitara et al. (19) | Pembrolizumab | PD-1 | Pembrolizumab vs. Paclitaxel | 570 | 41 | YES | III | RCT | Advanced gastric or gastro-oesophageal junction cancer |
| 7 | Powles et al. (20) | Atezolizumab | PD-L1 | Atezolizumab vs. Chemotherapy | 1,128 | 53 | Platinum-based | III | RCT | Locally advanced or metastatic urothelial carcinoma (UC) |
| 8 | Hida et al. (21) | Atezolizumab | PD-L1 | Atezolizumab vs. Docetaxel | 101 | 14 | Platinum-based | III | RCT | Locally advanced/metastatic NSCLC |
| 9 | Bellmunt et al. (22) | Pembrolizumab | PD-1 | Pembrolizumab vs. Chemotherapy | 521 | 28 | Platinum-based | III | RCT | Advanced Urothelial Carcinoma (UC) |
| 10 | Rittmeyer et al. (23) | Atezolizumab | PD-L1 | Atezolizumab vs. Docetaxel | 1187 | 89 | Platinum based | III | RCT | Squamous or non squamous NSCLC |
| 11 | Ferris et al. (24) | Nivolumab | PD-1 | Nivolumab vs. (Methotrexate, Docetaxel, or Cetuximab) | 347 | 8 | Platinum-based | III | RCT | Recurrent Squamous-Cell Carcinoma of the Head and Neck |
| 12 | Antonia et al. (25) | Nivolumab | PD-1 | Nivolumab vs. Nivolumab + Ipilimumab | 213 | 1 | Platinum-based | I/II | N/A | Recurrent SCLC |
| 13 | Fehrenbacher et al. (26) | Atezolizumab | PD-L1 | Atezolizumab vs. Doctaxel | 277 | 16 | Platinum-based | II | RCT | NSCLC |
| 14 | Herbst et al. (27) | Pembrolizumab | PD-1 | Pembrolizumab vs. Docetaxel | 991 | 33 | Platinum-containing | II/III | RCT | Advanced NSCLC |
| 15 | Borghaei et al. (28) | Nivolumab | PD-1 | Nivolumab vs. Docetaxel | 555 | 28 | Platinum-based | III | RCT | Non-squamous NSCLC |
| 16 | Brahmer et al. (29) | Nivolumab | PD-1 | Nivolumab vs. Docetaxel | 260 | 16 | Platinum-based | III | RCT | Squamous NSCLC |
| 17 | Mok et al. (30) | Pembrolizumab | PD-1 | Pembrolizumab vs. Chemotherapy | 1,241 | 51 | NO | III | RCT | NSCLC |
RCT, Randomized controlled trial; BCP, Bevacizumab plus Carboplatin plus Paclitaxel; NSCLC, Non-Small Cell Lung Cancer; PD-1, Programmed Cell Death 1; PD-L1, Programmed Cell Death Ligand 1; SCLC, Small Cell Lung Cancer; CP, Carboplatin plus Paclitaxel; PC, Pemetrexed plus a platinum-based drug; Chemotherapy, Carboplatin plus Pemetrexed, Cisplatin plus Pemetrexed, Carboplatin plus Gemcitabine, Cisplatin plus Gemcitabine, or Carboplatin plus Paclitaxel; N/A, No Available.